EPHORAN - Multi Imaging Solutions S.R.L. EPHORAN Multi Imaging Solutions, a Contract Research Organization based in Italy, provides a complete solution toolset for non-invasive in vivo preclinical imaging to study, develo p, and promote the application of imaging technologies in pre-clinical drug research and development.  Ephoran can provide preclinical imaging services covering all imaging techniques from those extensively used in clinical phases (e.g. MRI, PET, CT, SPECT, US, Opto-US) to Optical Imaging (OI, visible light and Near Infra Red – NIR), to assure a link between the preclinical and clinical studies.   Our facility is quipped with a 1, 3, ad 7T MRI imagers, hybrid PET/SPECT/CT and SPECT/PET imagers, ultrasound equipmet coupled to Photoacustic imaging system, bioluminescence, and fluorescence imaging instruments, along with radiochemistry and radiotherapy capabilities. For situation where one modality will not answer all your biological questions Ephoran is capable of combining funcional and anatomical data using a multimodal imaging system (PET/SPECT/CT syste m).   Our pre-clinical in vivo imaging systems offer solution for quantitation, deep tissue targeting, such as lung, heart, liver, kidney, GI, and brain in order to monitor and quantify in real time biological targets and pathways, giving a deeper understanding of the biology underlying disease mechanism and therapeutic response. Furthermore Ephoran provides a great variety of in vivo testing services including subcutaneous tumor models (xenograft tumor models), orthotopic tumor models, inflammation, CNS, hematoma, and others.   The in-house availability of a cyclotron for industrial production of clinical and preclinical tracers, such as 99-Tc, 18-F, 68-Ga, Y-90, and Lu-177, provides both PET/SPECT agents for custom labeling of candiate molecules.  More in detail Ephoran can: cu stom 68 Ga-, 18 F-, 111 In-, 177 Lu- and 99m Tc- labeled molecules (peptides, proteins or small molecules) in-house radiolabeled products: somatostatin analogues (targeting tumors overexpressing somatostatin type-2 receptors), RGD derivatives (targeting tumoral neo-angiogenesis), 18 FDG (targeting tumoral proliferating cells) and 18 F-DOPA (targeting tumoral cells and Parkinson disease), 99m Tc-rhAnnexin V-128 (multipurpose apoptosis targeting) in vivo distribution and diagnostic performance of radio-labeled molecules in several murine disease models (tumors, inflammation, neurodegenerative, etc…) in vivo efficacy of radiometabolic therapy with 177 Lu-radiolabelled molecules Ephoran also helps yo u prioritize the candidates in your pipeline by providing in vivo targeting and biodistribution data. This crucial data is best generated early in the decision-making process in order to select the candidates most likely to be successful in clinical studies.  Finally EPHORAN’s aim is to develop a strong and long lasting scientific collaborations with research institutions and companies in order to develop, accelerate, and and help the guiding the development of new diagnostic and therapeutic leads